A5039006383- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- CNS Lymphoma Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Hepatitis C virus research
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- Glycosylation and Glycoproteins Research
- Glioma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Erythrocyte Function and Pathophysiology
- Renal Diseases and Glomerulopathies
Azienda Sanitaria Universitaria Integrata di Trieste
2016-2025
University of Trieste
2019-2024
Ospedale Maggiore
2013-2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2013-2024
Ospedale Santa Maria della Misericordia di Udine
2011-2023
Hammersmith Hospital
2022
Imperial College London
2022
Centro di Riferimento Oncologico
2012-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Fondazione IRCCS Istituto Nazionale dei Tumori
2021
Over the last decade, there have been numerous developments and changes in treatment practices for management of patients with immune thrombocytopenia (ITP). This article is an update International Consensus Report published 2010. A critical review was performed to identify all relevant articles between 2009 2018. An expert panel screened, reviewed, graded studies formulated updated consensus recommendations based on new data. The final document provides diagnosis ITP adults, during...
BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard treatment for advanced Hodgkin's lymphoma, in place combination vinblastine, dacarbazine (ABVD).We randomly assigned 331 patients with previously untreated unfavorable lymphoma (stage IIB, III, or IV, international prognostic score ≥3 on a scale 0 to 7, higher scores indicating increased risk), receive either...
BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed safety and activity of oral inhibitor vemurafenib in patients with leukemia that had relapsed after treatment a purine analogue or who disease was refractory to analogues.
Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses a phase 2 ITP study. In two parallel, 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients persistent/chronic were randomized 2:1 fostamatinib (n = 101) or placebo 49) at 100 mg BID for 24 weeks dose increase...
Nongastrointestinal locations represent about 30% to 40% of all low-grade mucosa-associated lymphoid tissue (MALT) lymphomas. We report a retrospective analysis 75 patients with nongastrointestinal MALT lymphoma, presenting their clinical, therapeutic, and follow-up data respect the initial location lymphoma.From January 1988 October 1997, untreated lymphoma were subjected treatments ranging from local radiotherapy interferon alfa administration chemotherapy. The lymphomas located in lung...
Abstract Objective The pathogenetic role of B cells in rheumatoid arthritis (RA) is under debate, but it currently believed to be marginal. availability selective anti–B cell treatment provides a unique opportunity clarify this issue. This study was undertaken investigate the effects blockade refractory RA, and evaluate implications with regard disease. Methods Five female patients active, evolving erosive RA were treated rituximab, an anti‐CD20 chimeric monoclonal antibody. All 5 had been...
Objective. Rituximab, an anti-CD20 monoclonal antibody, has been used in lupus nephritis and membranous idiopathic nephropathy proved effective non-renal manifestations of type II mixed cryoglobulinaemia (MC) syndrome. We investigated the possible efficacy safety rituximab treatment cryoglobulinaemic nephritis.
The combination of bendamustine (B) and rituximab (R) is efficacious, with favorable toxicity in mantle-cell lymphoma (MCL). In this phase II study, we combined cytarabine R B (R-BAC) patients MCL age ≥ 65 years who were previously untreated or relapsed refractory (R/R) after one prior immunochemotherapy treatment.In stage one, established the maximum-tolerated dose (MTD) R-BAC. two, received (375 mg/m(2) intravenously [IV] on day 1), (70 IV days 2 3), (MTD to 4) every 28 for four six...
Purpose The pathogenic association between Chlamydophila psittaci (Cp) and ocular adnexal marginal zone lymphoma (OAMZL) the efficacy of doxycycline monotherapy have been investigated in retrospective series with variations stage, management, follow-up duration. To our knowledge, this is first international phase II trial aimed at clarifying Cp prevalence activity first-line a homogeneous consecutive patients newly diagnosed stage I OAMZL. Patients Methods Forty-seven were registered. Tumor...
Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, but it is not clear whether multiagent superior to MTX alone. Treatment options for recurrent lymphoma are limited; there no standard second-line chemotherapy. New chemotherapeutic agents activity needed treatment of disease. We report the results a phase II trial assessing alkylating agent temozolomide immunocompetent previously treated high-dose MTX-containing and/or radiotherapy. A median two...
Purpose The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, terms providing a rationale to shift who respond poorly onto more intensive regimen (PET response-adapted therapy), remains be confirmed. Patients and Methods phase II part the multicenter HD0801 study involved 519 de novo lymphoma received an initial treatment doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) underwent...